Show simple item record

dc.contributor.authorPowell, N
dc.contributor.authorIbraheim, H
dc.contributor.authorRaine, T
dc.contributor.authorSpeight, RA
dc.contributor.authorPapa, S
dc.contributor.authorBrain, O
dc.contributor.authorGreen, M
dc.contributor.authorSamaan, MA
dc.contributor.authorSpain, L
dc.contributor.authorYousaf, N
dc.contributor.authorHunter, N
dc.contributor.authorEldridge, L
dc.contributor.authorPavlidis, P
dc.contributor.authorIrving, P
dc.contributor.authorHayee, B
dc.contributor.authorTurajlic, S
dc.contributor.authorLarkin, J
dc.contributor.authorLindsay, JO
dc.contributor.authorGore, M
dc.coverage.spatialNetherlands
dc.date.accessioned2022-08-22T11:00:47Z
dc.date.available2022-08-22T11:00:47Z
dc.date.issued2020-07-01
dc.identifierS2468-1253(20)30014-5
dc.identifier.citationThe Lancet Gastroenterology & Hepatology, 2020, 5 (7), pp. 679 - 697en_US
dc.identifier.issn2468-1253
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5289
dc.identifier.eissn2468-1253
dc.identifier.eissn2468-1253
dc.identifier.doi10.1016/S2468-1253(20)30014-5
dc.description.abstractImmune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.
dc.formatPrint
dc.format.extent679 - 697
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIER INCen_US
dc.relation.ispartofThe Lancet Gastroenterology & Hepatology
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAdrenal Cortex Hormones
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAntineoplastic Agents, Immunological
dc.subjectConsensus
dc.subjectEndoscopy
dc.subjectEndoscopy, Digestive System
dc.subjectEnterocolitis
dc.subjectGastroenterology
dc.subjectGastrointestinal Diseases
dc.subjectGuidelines as Topic
dc.subjectHumans
dc.subjectInfliximab
dc.subjectLactoferrin
dc.subjectLeukocyte L1 Antigen Complex
dc.subjectNeoplasms
dc.subjectPatient Care Management
dc.subjectSocieties, Medical
dc.subjectTumor Necrosis Factor-alpha
dc.subjectUnited Kingdom
dc.titleBritish Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-01-21
dc.date.updated2022-08-22T11:00:22Z
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1016/S2468-1253(20)30014-5en_US
rioxxterms.licenseref.startdate2020-07-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/32553146
pubs.issue7
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.publication-statusPublished
pubs.volume5
dc.contributor.icrauthorTurajlic, Samra
dc.contributor.icrauthorLarkin, James
icr.provenanceDeposited by Mr Arek Surman on 2022-08-22. Deposit type is initial. No. of files: 1. Files: Lindsay_BSG endorsed guidance enterocolitis_Accepted_2020.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record